7Baggers

Ascendis Pharma Quarterly Balance Sheets Chart

Quarterly
 | 
Annual
 
 Cash and Cash Eq  
 Inventory  
20181231 20191231 20201231 20211231 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 096.06192.11288.17384.22480.28576.33672.39Thousand

Ascendis Pharma Quarterly Balance Sheets Table

Quarterly
 | 
Annual
 
Unit: USD2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31 2019-12-31 2018-12-31 
              
  assets            
  non-current assets            
  intangible assets4,301 4,419 4,495 4,606 4,717 4,828 4,939 5,050 5,272 5,717 3,495 3,495 
  property, plant and equipment107,164 110,634 125,535 125,362 127,762 129,095 139,345 133,224 126,049 108,112 45,069 4,325 
  investment in associates24,797            
  other receivables2,129 2,127 2,142 2,066 1,984 1,920 1,895 1,836 1,808 1,375 3,136 1,775 
  current assets            
  inventories232,681 208,931 189,132 167,919 150,850 130,673 103,975 101,322 75,405    
  trade receivables41,092 35,874 26,794 20,212 16,121 11,910 6,655 4,369 2,200 387  6 
  income tax receivables742 802 1,644 1,360 1,064 883 1,630 1,128 893    
  prepayments42,502 38,578 38,327 42,958 38,694 31,717 34,568 35,067 25,231 13,994 7,648 12,415 
  marketable securities     7,492 15,338 39,721 107,561 115,280   
  cash and cash equivalents320,239 392,164 441,268 394,222 501,281 444,767 608,330 672,387 446,267 584,517 598,106 277,862 
  total assets802,504 825,587 873,213 823,823 966,274 1,089,738 1,273,420 1,326,831 1,084,921 979,793 676,732 318,968 
  equity and liabilities            
  equity            
  share capital7,818 7,749 7,742 7,699 7,698 7,675 7,658 7,649 7,646 7,217 6,443 5,659 
  distributable equity-245,997 -153,446 -81,175 57,142 159,503 255,673 443,894 600,193 875,989 831,494 590,671 274,391 
  total equity-238,179 -145,697 -73,433 64,841 167,201 263,348   883,635 838,711 597,114 280,050 
  non-current liabilities            
  borrowings229,627 534,246 549,483 479,374 479,988 482,956 533,145 498,130     
  contract liabilities5,000 5,949 949 949 3,956 14,213 13,154 3,700 2,964 363 858 6,902 
  deferred tax liabilities7,085 5,830           
  current liabilities            
  convertible notes, matures in april 2028            
  derivative liabilities197,291 143,296 93,353 86,385 116,768 157,950 132,731 102,031     
  other current liabilities            
  trade payables and accrued expenses94,526 94,566 121,552 122,120 131,438 101,032 86,102 74,984 59,417 21,897   
  other liabilities22,698 41,176 33,660 22,860 15,503 31,989 26,578 20,957  3,162   
  income tax payables3,336 2,299 6,478 5,773  5,490   198    
  provisions40,550 32,719 20,781 10,811 9,154 7,339 6,799 5,018 1,193    
  total liabilities1,040,683 971,284 946,646 758,982 799,073 826,390 821,868 718,989 201,286 141,082 79,618 38,918 
  total equity and liabilities802,504 825,587 873,213 823,823 966,274 1,089,738 1,273,420 1,326,831 1,084,921 979,793 676,732 318,968 
  equity at january 1, 2024            
  net profit/(loss) for the period            
  other comprehensive income/(loss), net of tax            
  total comprehensive income/            
  transactions with owners            
  share-based payment            
  transfer under stock incentive programs            
  capital increase 398,966    638,023  683 528,548 215,693 132,496  
  equity at march 31, 2024            
  investment in associate 5,686 8,116 14,111 21,966 22,932 32,001 34,905 38,345 9,176 15,538 17,083 
  lease liabilities 84,619 90,103      97,966 85,116 30,720  
  equity at january 1, 2021 1,728,747           
  acquisition of treasury shares            
  cost of capital increase -19,974    -31,373   -31,701 -13,118 -8,388  
  equity at december 31, 2021 2,107,739    2,107,739   2,107,739    
  equity at december 31, 2022 2,112,863    2,112,863       
  net settlement under stock incentive programs            
  equity at december 31, 2023 2,123,074           
  equity at january 1, 2023            
  net profit / (loss) for the period            
  other comprehensive income / (loss), net of tax            
  total comprehensive income /            
  equity at september 30, 2023            
  equity at june 30, 2023            
  income taxes payable    6,873  126 90  301 119 9 
  equity at march 31, 2023            
  equity at january 1, 2020     1,122,097       
  equity at december 31, 2020     1,728,747   1,728,747 1,728,747   
  equity at january 1, 2022       2,107,739     
  equity at september 30, 2022            
  equity at june 30, 2022       2,108,422     
  equity at january 1, 2019        625,250    
  loss for the year            
  equity at december 31, 2019        1,122,097 1,122,097 1,122,097  
  equity at january 1, 2018         422,675   
  equity at december 31, 2018         625,250 625,250  
  deposits          1,463 1,158 
  receivable from associate          804  
  income taxes receivable          1,473 849 
  other payables          908 12,267 
  trade payables          27,765 19,740 
  equity at january 1, 2017          298,567  
  other comprehensive loss, net of tax            
  equity at december 31, 2017          422,675  
  equity at january 1, 2016            
  equity at december 31, 2016            

We provide you with 20 years of balance sheets for Ascendis Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ascendis Pharma. Explore the full financial landscape of Ascendis Pharma stock with our expertly curated balance sheets.

The information provided in this report about Ascendis Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.